Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Non-Diabetic NAFLD Patients
NCT05694923Completed
- Sponsor
- Assiut University
- Start
- Apr 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of empagliflozin in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Assiut University. Primary endpoint: Reduction in Hepatic Steatosis and Fibrosis at 3 months. Started Apr 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05694923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694923.